BCL2 and acute myeloid leukemia: This review focuses on the potential treatment strategies for AML involving a combination of FMS-like tyrosine kinase-3 (FLT3) inhibitors and B-cell lymphoma 2 (BCL-2) inhibitors and potential partners for this combination.